Quinoxaline derivatives as antitumor agents
US8518959B2 · kind B2 · utility
1Cited by
1References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 25, 2006 |
| Grant date | Aug 27, 2013 |
| Priority date | — |
| Expiry date | Apr 8, 2029 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/6872
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.